Just arrived back in the UK after giving the discussant lecture introducing the salivary cancer session at ASCO (American Society of Clinical Oncology) Annual Meeting in Chigago!
I introduced three salivary cancer trials which reported this weekend and am posting the details below for people to look up:
A phase 2 clinical trial of axitinib and avelumab in patients with recurrent/metastatic adenoid cystic carcinoma (ACC) by Dr Ferrarotto and colleagues.
https://ascopubs.org/doi/pdfdirect/10.1200/JCO.2022.40.16_suppl.6019
A phase 2 study of the oral vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor, rivoceranib, for recurrent or metastatic (R/M) adenoid cystic carcinoma (ACC) by Dr Kang and colleagues.
https://ascopubs.org/doi/pdfdirect/10.1200/JCO.2022.40.16_suppl.6020
Phase II study of trastuzumab-pkrb and docetaxel anhydrous combination therapy in recurrent or metastatic salivary ductal carcinomas (KCSG HN18-08/KM11) by Dr Lee and colleagues.
